Actively Recruiting
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
Led by Eva Bonfill · Updated on 2025-05-01
24
Participants Needed
1
Research Sites
122 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.
CONDITIONS
Official Title
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 65 years
- Documented asymptomatic HIV-1 infection lasting 3 to 12 months with positive Western blot including p31 band
- No prior antiretroviral therapy
- CD4 T-lymphocyte count greater than 350 cells per microliter
- Able and willing to provide written informed consent
You will not qualify if you...
- Active hepatitis B (HBsAg+ or DNA+) or hepatitis C (RNA+) infection at screening
- ALT greater than twice the upper normal limit
- Glomerular filtration rate less than 70 mL/1.73 m2
- Leukocytes fewer than 4000/mm3
- Total lymphocyte count fewer than 1000/mm3
- Platelet count fewer than 100,000/mm3
- Hemoglobin less than 12 g/dL
- Pregnancy or active breastfeeding
- History or presence of pleural effusion
- Chronic obstructive pulmonary disease, bronchial asthma, or recent chest trauma
- History of gastrointestinal or other bleeding
- Current use of drugs that may dangerously interact with dasatinib
- Any clinical condition judged by the investigator to contraindicate participation, including active cancer or active infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Eva Bonfill
Barcelona, Spain
Actively Recruiting
Research Team
E
Eva Bonfill
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here